

# SECURITIES AND EXCHANGE COMMISSION

## FORM SC 13G

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

Filing Date: **2004-05-18**  
SEC Accession No. **0001104659-04-014986**

([HTML Version](#) on [secdatabase.com](#))

### FILED BY

#### **HBM BIOVENTURES CAYMAN LTD**

CIK: **1232258**  
Type: **SC 13G**

Business Address  
*UNIT 10 EUCALYPTUS  
BUILDING  
P.O. BOX 30852  
GRAND CAYMAN A1 00000*

### SUBJECT COMPANY

#### **ANADYS PHARMACEUTICALS INC**

CIK: **1128495** | IRS No.: **223193172**  
Type: **SC 13G** | Act: **34** | File No.: **005-79854** | Film No.: **04815597**  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
*9050 CAMINO SANTA FE  
SAN DIEGO CA 92121*

Business Address  
*9050 CAMINO SANTA FE  
SAN DIEGO CA 92121  
8585303600*

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

**Anadys Pharmaceuticals, Inc.**

---

(Name of Issuer)

**Common Stock**

---

(Title of Class of Securities)

**03252Q 40 8**

---

(CUSIP Number)

**April 14, 2004**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No. 03252Q 40 8

---

- Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)  
HBM BioVentures (Cayman) Ltd.

---

- Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization  
Cayman Islands, British West Indies

5. Sole Voting Power  
1,499,418

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6. Shared Voting Power  
0

7. Sole Dispositive Power  
1,499,418

8. Shared Dispositive Power  
0

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,499,418

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)  
6.7%

12. Type of Reporting Person (See Instructions)  
PN

**Item 1.**

(a) Name of Issuer  
Anadys Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices  
9050 Camino Santa Fe  
San Diego, California

---

**Item 2.**

- (a) Name of Person Filing  
HBM BioVentures (Cayman) Ltd.
- 
- (b) Address of Principal Business Office or, if none, Residence  
Unit 10 Eucalyptus Building, Crewe Road, PO Box 30852 SMB  
Grand Cayman, Cayman Islands, British West Indies
- 
- (c) Citizenship  
Cayman Islands, British West Indies
- 
- (d) Title of Class of Securities  
Common Stock
- 
- (e) CUSIP Number  
03252Q 40 8
- 

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not applicable.

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:  
1,499,418
- 

- (b) Percent of class:

---

6.7%

---

(c) Number of shares as to which the person has:

---

(i) Sole power to vote or to direct the vote

1,499,418

---

(ii) Shared power to vote or to direct the vote

0

---

(iii) Sole power to dispose or to direct the disposition of

1,499,418

---

(iv) Shared power to dispose or to direct the disposition of

0

---

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

---

4

---

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

Not applicable.

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certification**

(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

Not applicable.

(b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

5

---

## Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 18, 2004

---

Date

/s/ John Arnold

---

Signature

John Arnold, Chairman and Managing Director

---

Name/Title